Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
-
Published:2020-05-12
Issue:1
Volume:6
Page:
-
ISSN:2374-4677
-
Container-title:npj Breast Cancer
-
language:en
-
Short-container-title:npj Breast Cancer
Author:
Amgad MohamedORCID, , Stovgaard Elisabeth Specht, Balslev Eva, Thagaard Jeppe, Chen Weijie, Dudgeon Sarah, Sharma AshishORCID, Kerner Jennifer K., Denkert Carsten, Yuan Yinyin, AbdulJabbar Khalid, Wienert Stephan, Savas PeterORCID, Voorwerk Leonie, Beck Andrew H., Madabhushi Anant, Hartman Johan, Sebastian Manu M., Horlings Hugo M., Hudeček JanORCID, Ciompi Francesco, Moore David A., Singh Rajendra, Roblin Elvire, Balancin Marcelo Luiz, Mathieu Marie-Christine, Lennerz Jochen K., Kirtani Pawan, Chen I-Chun, Braybrooke Jeremy P.ORCID, Pruneri Giancarlo, Demaria SandraORCID, Adams Sylvia, Schnitt Stuart J., Lakhani Sunil R., Rojo Federico, Comerma LauraORCID, Badve Sunil S.ORCID, Khojasteh Mehrnoush, Symmans W. FraserORCID, Sotiriou Christos, Gonzalez-Ericsson PaulaORCID, Pogue-Geile Katherine L., Kim Rim S., Rimm David L.ORCID, Viale Giuseppe, Hewitt Stephen M., Bartlett John M. S., Penault-Llorca Frédérique, Goel Shom, Lien Huang-Chun, Loibl Sibylle, Kos Zuzana, Loi ShereneORCID, Hanna Matthew G.ORCID, Michiels Stefan, Kok Marleen, Nielsen Torsten O., Lazar Alexander J.ORCID, Bago-Horvath ZsuzsannaORCID, Kooreman Loes F. S., van der Laak Jeroen A. W. M.ORCID, Saltz Joel, Gallas Brandon D.ORCID, Kurkure UdayORCID, Barnes Michael, Salgado Roberto, Cooper Lee A. D.ORCID
Abstract
AbstractAssessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical translation in this arena. Specifically, we discuss: 1. ensuring computational workflows closely capture visual guidelines and standards; 2. challenges and thoughts standards for assessment of algorithms including training, preanalytical, analytical, and clinical validation; 3. perspectives on how to realize the potential of machine learning models and to overcome the perceptual and practical limits of visual scoring.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology
Reference97 articles.
1. Piccart-Gebhart, M. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or Trastuzumab Treatment Optimization Trial. J. Clin. Oncol. 34, 1034–1042 (2016). 2. von Minckwitz, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122–131 (2017). 3. Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010). 4. Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228–241 (2016). 5. Burns, P. B., Rohrich, R. J. & Chung, K. C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 128, 305–310 (2011).
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|